Table 2.
Complete relief of IBS symptoms following rifaximin treatment
|
Patients, n (%) |
||
|---|---|---|
| Rifaximin 1200 mg/day (n = 162) | Rifaximin 2400 mg/day (n = 81) | |
| All IBS | ||
| Global symptoms | 19 (12) | 9 (11) |
| Abdominal pain | 15 (9) | 2 (2) |
| Bloating | 17 (10) | 5 (6) |
| Constipation | 9 (6) | 4 (5) |
| Diarrhea | 15 (9) | 8 (10) |
| Gas | 16 (10) | 5 (6) |
| IBS-Da | ||
| Global symptoms | 5 (11) | 3 (13) |
| Abdominal pain | 5 (11) | 0 (0) |
| Bloating | 6 (13) | 1 (4) |
| Constipation | 0 (0) | 0 (0) |
| Diarrhea | 6 (13) | 4 (17) |
| Gas | 4 (9) | 1 (4) |
| IBS-Ca | ||
| Global symptoms | 4 (12) | 1 (6) |
| Abdominal pain | 3 (9) | 0 (0) |
| Bloating | 2 (6) | 0 (0) |
| Constipation | 4 (12) | 1 (6) |
| Diarrhea | 1 (3) | 0 (0) |
| Gas | 4 (12) | 1 (6) |
| IBS-Ma | ||
| Global symptoms | 4 (17) | 2 (18) |
| Abdominal pain | 3 (13) | 0 (0) |
| Bloating | 4 (17) | 1 (9) |
| Constipation | 3 (13) | 0 (0) |
| Diarrhea | 4 (17) | 2 (18) |
| Gas | 3 (13) | 1 (9) |
Note:
a
Patients not subclassified as IBS-D, IBS-C, or IBS-M were not included in this analysis.
Abbreviations: IBS, irritable bowel syndrome; IBS-D, diarrhea-predominant irritable bowel syndrome; IBS-C, constipation-predominant irritable bowel syndrome; IBS-M, mixed-symptom irritable bowel syndrome.